A Novel Hybrid Promoter ARE-hTERT for Cancer Gene Therapy
| Autor: | P. N. Vikhreva, S. V. Kalinichenko, M. V. Shepelev, Igor V. Korobko |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Uracil phosphoribosyltransferase Chemistry GCLM Cytosine deaminase Promoter Biochemistry Fusion protein 03 medical and health sciences 030104 developmental biology 0302 clinical medicine 030220 oncology & carcinogenesis embryonic structures Cancer cell Cancer research Molecular Medicine Telomerase reverse transcriptase Molecular Biology Transcription factor Biotechnology |
| Zdroj: | Acta Naturae. 9:66-73 |
| ISSN: | 2075-8251 |
| DOI: | 10.32607/20758251-2017-9-4-66-73 |
| Popis: | describe a novel hybrid tumor-specific promoter, ARE-hTERT, composed of the human TERT gene promoter (hTERT) and the antioxidant response element (ARE) from the human GCLM gene promoter. The hybrid promoter retains the tumor specificity of the basal hTERT promoter but is characterized by an enhanced transcriptional activity in cancer cells with abnormal activation of the Nrf2 transcription factor and upon induction of oxidative stress. In the in vitro enzyme-prodrug cancer gene therapy scheme, ARE-hTERT promoter-driven expression of CD : UPRT (yeast cytosine deaminase : uracil phosphoribosyltransferase) chimeric protein induced a more pronounced death of cancer cells either upon treatment with 5-fluorouracil (5FC) alone or when 5FC was combined with chemotherapeutic drugs as compared to the hTERT promoter. The developed hybrid promoter can be considered a better alternative to the hTERT promoter in cancer gene therapy schemes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|